{"entity":{"id":"nct04243499","kind":"trial","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","aka":[],"tldr":"A phase 1/2 trial of IV ICT01 in advanced solid tumours, run by ImCheck Therapeutics, an Ipsen company, active and no longer recruiting.","summary":"First-in-Human Study of ICT01 in Patients With Advanced Cancer is a phase 1/2 interventional study registered as NCT04243499 by ImCheck Therapeutics, an Ipsen company, with 293 participants enrolled, started 2020-03-05 and due to reach its primary completion in 2027-10-15. Interventions recorded: IV ICT01.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04243499","url":"https://clinicaltrials.gov/study/NCT04243499"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04243499","phase":"1/2","setting":"A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer","sponsor":"ImCheck Therapeutics, an Ipsen company","enrolled":293,"outcomes":[]},"route":"/trials/nct04243499/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}